Tumor necrosis factor (TNF-␣) underlies pathological processes and functional disturbances in acute and chronic neurological disease and injury. The neuroimmunomodulatory peptide ␣-MSH modulates actions and production of proinflammatory cytokines including TNF-␣, but there is no prior evidence that it alters TNF-␣ induced within the brain. To test for this potential influence of the peptide, TNF-␣ was induced centrally by local injection of bacterial lipopolysaccharide (LPS). ␣-MSH given once i.c.v. with LPS challenge, twice daily intraperitoneally (i.p.) for 5 d between central LPS injections, or both i.p. and centrally, inhibited production of TNF-␣ within brain tissue. Inhibition of TNF-␣ protein formation by ␣-MSH was confirmed by inhibition of TNF-␣ mRNA. Plasma TNF-␣ concentration was elevated markedly after central LPS, indicative of an augmented peripheral host response induced by the CNS signal. The increase was inhibited by ␣-MSH treatments, in relation to inhibition of central TNF-␣. Presence within normal mouse brain of mRNA for the ␣-MSH receptor MC-1 suggests that the inhibitory effects of ␣-MSH on brain and plasma TNF-␣ might be mediated by this receptor subtype. The inhibitory effect of ␣-MSH on brain TNF-␣ did not depend on circulating factors because the effect also occurred in brain tissue in vitro. This indicates that ␣-MSH can act directly on brain cells to inhibit their production of TNF-␣. If central TNF-␣ contributes to pathology in CNS disease and injury, and promotes inflammation in the periphery, agents that act on brain ␣-MSH receptors should decrease the pathological TNF-␣ reaction and promote tissue survival.
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With improvement in understanding of cytokine mediators of inflammation and with recent identification of these mediators in certain CNS diseases, it is likely that the importance of inflammatory cytokines and processes in all CNS injuries and disorders will eventually be recognized. Although several inflammatory cytokines likely contribute to CNS inflammation, TNF-␣ may be especially important in CNS disease. TNF-␣ has been linked to multiple sclerosis, HIV infection of the CNS, Alzheimer's disease, meningitis, and acute brain injury as a result of ischemia /reperfusion or of trauma.
TNF-␣ occurs in abundance in lesions of multiple sclerosis, which, with its capacity to promote myelin destruction and to increase adhesion molecule expression, makes it a prime suspect in etiology of the lesions (Raine, 1994) . Expression of TNF-␣ mRNA predominates in perivascular inflammatory cuffs rather than in parenchymal cells, suggesting that circulating inflammatory cells that have entered the brain are the major source of the cytokine in this disease (Woodroofe and Cuzner, 1993) . Experimental multiple sclerosis is improved by anti-TNF-␣ antibodies and by soluble TNF-␣ receptors (Selmaj and Raine, 1995) . Direct infection of neurons by HIV is not responsible for manifestation of neurological disease. Rather, it seems that macrophages and /or microglia are affected and thereby alter the functions of neurons and glia via release of proinflammatory cytokines such as TNF-␣ (Koka et al., 1995; Tyor et al., 1995) . The cytokines promote dysmyelination and inflammation, and neurological symptoms result. It seems that the HIV envelope protein gp120 is toxic to human brain cell cultures through induction of TNF-␣ and interleukin 6 (Yeung et al., 1995) . It has been known for some time that portions of the HIV envelope protein induce TNF-␣ in primary brain culture (Merrill et al., 1992 ). Alzheimer's disease, marked by progressive intellectual failure, is characterized by formation within the brain of aggregates of ␤-amyloid protein and infiltration of reactive microglia and astrocytes. Recent evidence suggests that in this disorder, microglia-induced neuronal injury stems from a synergistic effect of ␤-amyloid protein and interferon-␥ in triggering production of proinflammatory and toxic TNF-␣ and nitrogen intermediates (Meda et al., 1995) . TNF-␣ has been observed in CSF of patients with bacterial meningitis (Glimaker et al., 1993; Dulderian et al., 1995) and in experimental bacterial meningitis I (Kimberlin et al., 1995) . There is evidence that such increases are a result of elevated production of TNF-␣ by ependymal cells of the choroid plexus (Tarlow et al., 1993) . In experimental brain ischemia /reperfusion, TNF-␣ mRNA appears early and precedes infiltration of inflammatory cells into the injured zone (Feuerstein et al., 1994) . It is found early in neurons, in and around ischemic tissue, and later in macrophages in infarcted tissue. The cytokine concentration is increased in the CSF of victims of traumatic head injury (Ross et al., 1994) .
If TNF-␣ causes or promotes pathology in multiple CNS disorders, agents that inhibit its production should preserve neuro-logical function. A neuroimmunomodulatory peptide, ␣-MSH, is known to inhibit the in vivo and in vitro actions and production of proinflammatory cytokines (Lipton and Catania, 1991 , but no tests have been performed on the influence of the peptide on TNF-␣ production induced within the brain. The main purpose of the present investigations was to determine whether ␣-MSH inhibits central production of TNF-␣ in vivo and in vitro.
MATERIALS AND METHODS
Animals. The experiments were approved by the local Internal Review Board for Animal Research. Male BALB/c mice (Simonsen Laboratories, Gilroy CA), ϳ20 gm body weight, were housed at 23-25ЊC in groups not exceeding five animals per cage [28 cm (length) ϫ 18 cm (width) ϫ 13 cm (height)]. Before the experiments, the mice were acclimatized to standard lighting and temperature conditions with food and water freely available.
Influence of ␣-MSH treatments on brain TNF-␣ in vivo. ␣-MSH 1-13 obtained from Sigma (St. Louis, MO) was dissolved in saline just before injection. For determinations of in vivo brain TNF-␣ protein and mRNA, and for MC-1 mRNA, brains were removed 1 hr after LPS administration. At the time of decapitation, trunk blood was collected in lightly heparinized 1.5 ml tubes. The LPS used to promote TNF-␣ production was derived from Salmonella typhosa (Difco, catalog #0901). Saline (20 l) or LPS (5 g) in saline was injected into the cerebral ventricles of mice anesthetized with ether using procedures described previously (Lipton et al., 1991; Lipton and Catania, 1993) . ␣-MSH (10 g) for i.c.v. injection was likewise dissolved in 0.1 l saline. Intraperitoneal injections of ␣-MSH (50 g) or saline vehicle were 0.1 ml in volume.
Influence of ␣-MSH on TNF-␣ production by brain tissue in vitro. Brains were dissected intact, immediately sectioned midsagittally, and the halves were weighed and placed in 1 ml medium (DMEM with 10% FBS, 2 mM L-glutamine, 200 U/ml penicillin, and 200 g/ml streptomycin) in individual wells of a 24-well plate. Each sample was minced with a scalpel blade and washed with medium. After 15 min at room temperature, the washing was repeated. LPS (2.5 g), LPS ϩ ␣-MSH, or medium control was added to wells containing 500 l of DMEM, and incubation at 37ЊC was continued for 1 hr. Ten microliters of supernatant from each well were assayed for TNF-␣ concentration.
TNF-␣ determinations. Concentrations of TNF-␣ in brain and plasma were determined with an L929 cell cytotoxicity assay, with human TNF-␣ used as control and for production of standard curves. The triplicate samples were incubated overnight with L929 cells in medium containing 100 g/ml cyclohexamide (Sigma) in 96-well plates. The TNF-␣ concentrations were determined with reference to intensity at 550 nm in an ELISA plate reader (BT 2000, Fisher-Biotech) . Each plate contained standards.
Northern analysis for TNF-␣ mRNA. RNA was isolated by homogenization in guanidinium thiocyanate followed by phenol/chloroform extraction. Total RNA (15 g) was fractionated on a formaldehyde-denaturing agarose gel and transferred overnight to a nylon membrane that was subsequently baked at 80ЊC for 1 hr. The membrane was prehybridized for 6 hr at 42ЊC with a solution containing 2ϫ Denhardt's reagent, 100 g/ml salmon sperm DNA, 40% formamide, 4ϫ SSC, 7 M Tris, pH 7.4, and 3% SDS. cDNA probe was radiolabeled with [ 32 P]dCTP (3000 Ci/mmol; DuPont NEN) by random primer labeling (Prime-a-Gene Labeling System, Promega). The blot was hybridized overnight with 1-2 ϫ 10 6 cpm/ml probe for mouse TNF-␣ at 42ЊC in the same solution. Blots were then washed three times in 2ϫ SSC and 0.1% SDS at room temperature for 15 min, and then two more times for 30 min at high stringency (0.1ϫ SSC, 0.1% SDS, 68ЊC). The blot was then exposed to X-ray film with 2 intensifying screens at Ϫ70ЊC for 2-3 d. Ethidium bromide was used to evaluate equivalence of RNA loading.
Determination of melanocortin 1 receptor mRNA. Total RNA (200 g) was isolated from normal mouse brain by guanidinium thiocyanate, phenol, chloroform extraction and used to generate cDNA. Genomic DNA was digested with DNase in reverse transcriptase (RT) buffer for 30 min at 37ЊC. The DNase was inactivated by phenol-chloroform extraction. cDNA was produced using Moloney murine leukemia virus RT (BRL, Gaithersburg, MD). In some tubes, the RT was omitted to control for amplification from contaminating cDNA or genomic DNA. Portions of the cDNA were used for PCR with primer pairs specific for the murine MC-1 isoform (529 bp). The forward primer was (5Ј to 3Ј) GTGAGTCT-GGTGGAGAATGTGC and the reverse primer was TTTTGTG-GAGCTGGGCAATGCC. The primers were chosen in regions of low similarity among known MC receptors. PCR mixtures contained: 1 M primers, 1.5-2.5 mM MG 2ϩ , 200 M dNTP, 1ϫ reaction buffer, 1 U of Taq DNA polymerase, and 5 l cDNA in 20 l. The PCR profile consisted of 35 cycles of 94ЊC for 45 sec, 60ЊC for 45 sec, and 72ЊC for 75 sec, followed by a 5 min final extension at 72ЊC. The PCR products were size fractionated by agarose gel electrophoresis, transferred to nylon membrane, and hybridized with a 32 P end-labeled internal oligo probe specific for the MC-1 receptor (5Ј to 3Ј) CAGCATCGTCTCCAGCACCCTC.
Statistical analysis. Data were analyzed using one-way ANOVA procedures, followed by Dunnet's test for multiple comparisons of group means.
RESULTS

Brain TNF-␣ protein and mRNA
Concentrations of TNF-␣ protein in control brains harvested after i.c.v. administration of LPS were markedly increased (Fig. 1) , whereas in experiments on brains of normal untreated mice, TNF-␣ was low or undetectable (data not shown). All of the ␣-MSH treatments inhibited TNF-␣ protein production within the brain. A single central injection of the peptide greatly reduced TNF-␣ concentration, a similar inhibition was observed in animals given ␣-MSH intraperitoneally (i.p.) twice daily for 5 d (final ␣-MSH injection ϳ16 hr before the second LPS injection), and the greatest inhibition occurred in mice given ␣-MSH systemically for 5 days as well as centrally at the time of LPS injection, 1 hr before brains were removed. These results indicate that a single dose of centrally injected peptide acts rapidly to inhibit local TNF-␣ production. Further, this single injection is as effective as repeated systemic injections of ␣-MSH. Given the positive effects of central and systemic ␣-MSH injections, it is not surprising that the greatest inhibition occurred in mice given ␣-MSH by both routes. The inhibitory influence of ␣-MSH on central TNF-␣ was confirmed by Northern analysis of TNF-␣ mRNA abundance (Fig. 2) .
Plasma TNF-␣
Central administration of LPS markedly increased circulating TNF-␣ in animals that did not receive ␣-MSH treatment (Fig. 3) . These 
Evidence of MC-1 receptor expression in the brain
To test the idea that the primary ␣-MSH receptor MC-1, recently found in murine macrophages and in human macrophages and neutrophils (Star et al., 1995; Rajora et al., 1996; Catania et al., 1996) , likewise occurs in brain tissue, normal mouse brain was subjected to RT-PCR and Southern analysis. This analysis revealed a substantial signal at 529 bp, consistent with the size of the cDNA for the murine MC-1 receptor (Fig. 4) . Control analysis of other murine tissues (e.g., lung), and of cells of the L929 fibroblast line used for TNF-␣ determinations, did not show any evidence of MC-1 expression.
Effect of ␣-MSH on TNF-␣ production by brain tissue in vitro
If, as the results above suggest, ␣-MSH acts centrally to inhibit TNF-␣ production, the peptide may reduce production of the cytokine by brain cells per se, without the influence of factors in the blood supply in the live animal. To test this idea, brain samples were incubated with LPS (2.5 g), and with LPS ϩ concentrations of ␣-MSH for 1 hr, and samples of medium were analyzed for TNF-␣. Marked increases in TNF-␣ were induced by LPS in control tissue. ␣-MSH inhibited TNF-␣ production in a doserelated fashion (Fig. 5 ), which indicates a direct effect of the peptide on brain cells that produce the cytokine. These results demonstrate that no secondary influence of ␣-MSH via circulating mediators is necessary for the inhibition.
Brain TNF-␣ mRNA after a single injection of LPS
In view of reports of CNS tolerance to central LPS administration (Faggioni et al., 1995) , the effect of single LPS (5 g) injections into the brain was tested in otherwise untreated mice. These injections resulted in the greatest abundance of brain TNF-␣ mRNA observed in this study (Fig. 6 ). This result indicates that the greatest effect of LPS on TNF-␣ expression within the brain occurs after the first injection and, with evidence of lesser abun- dance after a second injection made 5 d later, supports the idea of CNS tolerance to LPS treatment. DISCUSSION TNF-␣ within the brain ␣-MSH acts locally within the brain to inhibit production of TNF-␣ both in vivo and in vitro. Central injection of ␣-MSH inhibited TNF-␣ production, and expression of TNF-␣ mRNA, in live mice within 1 hr after local injection of LPS. This result was confirmed in vitro by marked inhibition by ␣-MSH of TNF-␣ production by brain tissue. These converging observations indicate that the neuropeptide ␣-MSH modulates brain TNF-␣ concentration via actions directly within the parenchyma. The cell source of this rapid increase in TNF-␣ was not determined; however, it is clear that astrocytes (for example, see Kimberlin et al., 1995) as well as microglia (for example, see Meda et al., 1995) and ependymal cells (for example, see Tarlow et al., 1993) can produce the cytokine.
Systemically administered ␣-MSH inhibits brain TNF-␣ production Repeated i.p. injections of ␣-MSH likewise inhibited the increase in brain TNF-␣ caused by central injection of LPS, and the combination of central and systemic ␣-MSH injections had the greatest inhibitory effect. This observation suggests that repeated systemic administration of ␣-MSH alters the reactivity of brain cells to LPS stimulation, although the mechanisms underlying this alteration are unknown. It is notable that the greatest inhibitory effect on TNF-␣ production was caused by repeated administration of ␣-MSH and of acute central administration of the peptide. It may be that the latter effect results from a combination of influences induced by centrally injected ␣-MSH acting within the brain, and systemically injected ␣-MSH acting on peripheral host cells and on brain melanocortin receptors. There is direct evidence that ␣-MSH administered systemically reaches the brain (Wilson, 1988) , albeit in small amounts. Further, systemically administered ␣-MSH reduces fever in minutes, an antipyretic effect that can occur only through an action of the peptide within the CNS. This observation is very important for potential clinical use of ␣-MSH to control TNF-␣ production in animals or humans in whom local brain injections are unsafe or impractical. One of the main questions is whether ␣-MSH could be administered before neurosurgical procedures and thereby modulate local inflammatory responses to surgery or contamination. In keeping with this idea, in recent research on basilar artery ischemia / reperfusion in dogs (Huh et al., 1997) , disturbance of the brainstem auditory evoked potential was less in animals given ␣-MSH IV, particularly when it was administered during ischemia.
Central LPS markedly increases circulating TNF-␣
It is remarkable that a small amount of LPS injected into the brain promotes not only local TNF-␣ production but circulating TNF-␣ even moreso. This observation, noted previously (Faggioni et al., 1995) , has far-reaching implications. In brief, it may be that the induction of central TNF-␣, or a more direct action of LPS within the brain, causes marked increases in production of TNF-␣ within the circulation, presumably by monocytes. Because the concentrations of TNF-␣ induced within the brain are substantially less than those induced in the circulation, it is unlikely that the circulating TNF-␣ originates from the brain. The nature of the signals from brain to the periphery are not clear. TNF-␣-producing cells in the brain may invoke neural and /or humoral signals. Nor is the physiological significance of the phenomenon known, although it may be that sensing of central TNF-␣ promotes circulating TNF-␣ to counteract challenges to the host. Such an increase in circulating TNF-␣ after central LPS may explain the increase in peripheral inflammation after central injection of "endogenous pyrogen" (EP, Dulaney et al., 1992) . In those experiments, central administration of undiluted EP significantly increased peripheral inflammation in the mouse; dilutions of EP had lesser or no effects. A proinflammatory influence of central TNF-␣ could be detrimental in organisms with preexisting inflammatory disease in the periphery; for example, central TNF-␣ might promote peripheral inflammation in rheumatoid arthritis or inflammatory bowel disease by inducing high concentrations of the cytokine in the bloodstream. Central ␣-MSH modulates the increase in circulating TNF-␣ induced by LPS acting solely within the brain Whatever the basis of the increase in circulating TNF-␣, injection of ␣-MSH into the brain reduced it. The dose of ␣-MSH that inhibited circulating TNF-␣ effectively reduced peripheral inflammation after central injection in earlier experiments (Lipton et al., 1991; Ceriani et al., 1994; Macaluso et al., 1994) . If circulating TNF-␣ contributes to the inflammatory response in the periphery, central ␣-MSH likely inhibits this inflammation in some part by modulating circulating TNF-␣. It is clear that descending neurogenic anti-inflammatory pathways in the spinal cord are necessary for the anti-inflammatory actions of central ␣-MSH . It may be that these pathways are the means through which central ␣-MSH modulates production of TNF-␣ by peripheral host cells, although it is likely that modulation of release of peripheral substance P and calcitonin gene-related peptide is also responsible.
Effects of systemic ␣-MSH
The results indicate that systemically administered ␣-MSH inhibits circulating TNF-␣ concentration. There are three potential mechanisms: (1) a direct inhibitory action on TNF-␣ producing cells (e.g., monocytes) in the circulation, (2) an effect of the ␣-MSH that penetrates to the brain on central descending anti-inflammatory pathways, or (3) some combination of these two. That ␣-MSH inhibits release of proinflammatory mediators from monocytic cells is clear; we have noted ) that TNF-␣ production by human peripheral blood mononuclear cells is inhibited by ␣-MSH, which indicates that a direct effect of the peptide on melanocortin receptors on monocytes is possible. As stated above, ␣-MSH injected systemically is known to reach the brain and may, therefore, inhibit TNF-␣ production in the circulation via unknown pathways. Finally, it is clear that ␣-MSH can alter inflammatory processes by acting directly on host cells in the periphery and by acting within the brain. Because systemic ␣-MSH is available at both sites, it is reasonable to assume that the peptide acts at both these sites.
Evidence for MC-1 receptors within the brain
The inhibitory effects of ␣-MSH on TNF-␣ production by brain tissue in vivo and in vitro indicates that receptors for the peptide reside within the brain. Indeed, there is prior evidence for three melanocortin receptor subtypes in brain: MC-3, MC-4, and MC-5 (Hol et al., 1995) . Further, our RT-PCR evidence supports observations made in in situ hybridization and immunohistochemistry experiments (Xia et al., 1995) that the MC-1 receptor is likewise expressed in brain tissue. MC-1 may therefore contribute to the anti-TNF-␣ activity of the peptide. It is not yet possible to determine the precise contribution of the melanocortin receptor subtypes to inhibition of TNF-␣ production; all four subtypes found within the brain respond to ␣-MSH and may therefore contribute to its anti-inflammatory effect. However, it should be possible to test the relative contributions of the receptor subtypes to modulation of TNF-␣ production in whole brain by incubating brain tissue with antibodies to them.
In summary, the results extend to the CNS the observations of the anti-inflammatory effects of the neuropeptide ␣-MSH. Inflammation in peripheral tissues is modulated by ␣-MSH acting on its receptors on neutrophils and macrophages and those within the brain. The rapid anti-TNF-␣ effects of ␣-MSH within brain tissue per se likely occur via direct actions of the peptide on local brain cells (astrocytes and microglia) that produce TNF-␣. Modulation of circulating TNF-␣ via ␣-MSH-induced inhibition of central cytokine signals provides a new avenue for control of peripheral inflammatory reactions, via actions on melanocortin receptors within the brain.
